Skip to main content
OpenTrials
Completed

NCT Number: NCT05838911

Does Neuromuscular Electrical Stimulation Benefit the Functional Ability of Elderly Patients With Chronic Obstructive Lung Disease

Background: Patients with COPD often experience skeletal muscle dysfunction. For those who are unable or unwilling to undertake physical training, neuromuscular electrical stimulation (NMES) may provide an alternative method of exercise training.

Objective: To investigate the effects of adding neuromuscular electrical stimulation of gluteus maximus, quadriceps and calf muscles to chest physiotherapy, compared to chest physiotherapy alone, on muscles strength (gluteus max., quadriceps, calf muscles), femoral blood flow physical and pulmonary function in severe COPD Patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Rehabilitation Chronic Disease Chronic Obstructive Lung Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Neuromuscular Electrical Stimulation Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Pulmonary Function (FEV1/FVC) Respiratory Tract Diseases

Age range

65 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of P.T for internal medicine, Faculty of Physical Therapy, South valley university, Qena, Egypt

Qina, Egypt

About this study

Material and methods: This study include a group of 60 patients (30 males and 30 females) diagnosed with severe COPD), their age is ranged 65-75 years, they will be randomly divided into two groups; study group (A) 30 patients and study group (B) 30 patients. Study group (A): The patients in this group will receive the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks. Study group (B): The patients in this group will receive the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, calf muscles, performed for 30 min /day for five days a week for three consecutive weeks. Femoral blood Flow, gluteus maximus, quadriceps and calf muscles strength and pulmonary function (FEV1/FVC) will be measured for both groups pre and post treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A diagnosis of COPD with FEV1/FVC <50% predicted as per the GOLD guidelines.
  • Self-reported dyspnea and/or arm fatigue during at least one activity of daily living that required arm exercise.
  • Dyspnea and/or physical activity fatigue were self-reported by the Borg Scale.
  • Before entering in the study, all patients had their pulmonary function optimized with long-acting bronchodilators and corticosteroids.

Exclusion criteria

  • • Patients with unstable angina pectoris.
  • Progressive ventricular dysrhythmia.
  • Intermittent claudication.
  • Implanted cardiac pacemakers.
  • Uncontrolled diabetes mellitus.
  • Peripheral vascular disease.

Treatment and study plan

Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)

Other

The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.

Other names: Chest physical therapy plus NMES

Control Group Chest physical therapy

Other

The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks

Other names: Chest physical therapy

Primary outcomes

  1. Six-minute walking test (Physical function assessment

    Time frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up

    The six-minute walking distance (6MWD) was measured according to a standardized protocol.

    • Subjects were instructed to walk at their own pace along a 34.5-m corridor from one end to the other, covering as much ground as possible in the allotted time.
    • Subjects were allowed to stop and rest during the test, but they were instructed to resume walking as soon as they felt able to do

  2. Pulmonary function test

    Time frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up

    Pulmonary capacity and respiratory muscle functions will be assessed using the CPFS/D USB™ 187 Spirometer (Medical Graphics-MGC, St. Paul, MN, USA) with airflow being measured by a 188 calibrated Pitot tube (PreVent, Pneumotach). The participant completed at least three acceptable maximal forced and slow expiratory maneuvers after 15 min the inhalation of 400 mg of salbutamol 190 via a metered-dose inhaler. Forced vital capacity (FVC, L), forced expiratory volume in one second (FEV1, L), FEV1/ FVC, and inspiratory capacity (IC) will be measured according to American Thoracic Society standards

  3. Muscle strength measurement

    Time frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up

    To determine the maximal muscle strength the Lafayette manual muscle test system (USER MANUAL) (MMT) Model 01163, White Plains, New York (10602) of gluteus maximus, quadriceps and calf muscles will be measured on right lower limb.

Secondary outcomes

  1. Blood flow velocimetry measurement

    Time frame: change from baseline to 3 weeks after intervention and 3 days as a follow-up

    To evaluate changes in peripheral perfusion. The standard pulsed-wave Doppler velocimetry of the right femoral artery was performed using sonos 2000 echograph (Philips Envisor )

Sponsors and collaborators

Lead sponsor

Beni-Suef University

Other

Collaborators

  • South Valley University

Registry information

Acronym: NEMS for COPD

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
May 3, 2023
Registry last updated
Apr 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.